不过，也有少量药物调低价格。约9种药物将降价，其中包括勃林格殷格翰（Boehringer Ingelheim）糖尿病药物Jardiance及相关三款药 物，降幅超过40%。Jardiance是2026年美国政府为65岁及以上医保计划谈判降价的10款药物之一，两家公司将该药价格下调约三分之 二。 美国患者目前支付的处方药费用远高于其他发达国家，往往是其他国家的近三倍。特朗普一直要求药企将美国药价降至类似富裕国家的 水平。然而，即便特朗普已与14家药企达成部分药物价格协议，这些公司仍计划在1月1日提高部分药物价格。涉及公司包括辉瑞 （Pfizer）、赛诺菲（Sanofi）、勃林格殷格翰、诺华（Novartis）和葛兰素史克（GSK）。 整理 | GLP1减重宝典内容团队 尽管特朗普政府一直施压药企降低药价，但美国制药公司计划在2026年提高至少350种处方药的价格，其中包括针对新冠、呼吸道合胞 病毒（RSV）和带状疱疹的疫苗，以及抗癌重磅药物伊布替尼（Ibrance）。 与去年同期相比，今年的涨价药品数量有所增加——去年同期约为250种。今年的涨幅中位数约为4%，与2025年持平。这些价格调整仅 指药品标价，不包 ...

This big pharma stock still faces significant challenges in the new year.A rising tide doesn't lift all boats. For example, a boat with gaping holes in its hull will sink regardless of how high the tide rises. Pfizer (PFE 0.59%) seemed to be the investing equivalent of such a boat in 2025.Shares of the pharmaceutical giant declined 6% last year, experiencing several significant fluctuations along the way. Can Pfizer's stock bounce back in 2026? NYSE : PFEPfizerToday's Change( -0.59 %) $ -0.15Current Price$ ...

Pfizer Inc. (PFE), headquartered in New York, discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products. With a market cap of $143.2 billion, the company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. The pharmaceutical giant is expected to announce its fiscal fourth-quarter earnings for 2025 before the market opens on Tuesday, Feb. 3. Ahead of the event, analysts ex ...

Pfizer Inc. (NYSE:PFE) is included among the 13 Best January Dividend Stocks to Invest in. Pfizer (PFE) Plans Price Increases on About 80 Medicines Despite Broader Pricing Deals Pfizer Inc. (NYSE:PFE) is among the drugmakers planning to raise prices on some medicines starting January 1. The increases will affect about 350 drugs, even as President Donald Trump has reached agreements with 14 pharmaceutical companies to lower prices on certain treatments for the government’s Medicaid program and for cash-pa ...

Core Viewpoint - Pfizer's dividend is considered relatively safe as 2026 begins, despite concerns regarding its high payout ratios and upcoming patent expirations [1][12][14] Financial Performance - Pfizer reported earnings of over $9.4 billion in the first nine months of 2025, with a market capitalization exceeding $140 billion [1] - The company has a forward dividend yield of 6.9% and a high dividend payout ratio of 99.4%, indicating it is barely covering its dividend with earnings [3][1] Cash Flow Analysis - Pfizer generated free cash flow of $10.4 billion in the 12 months ending September 30, 2025, while paying out $9.7 billion in dividends, resulting in a free cash flow payout ratio of 93.3% [6][12] - The free cash flow payout ratio is viewed as less concerning compared to the earnings-based payout ratio [12] Dividend History - Pfizer has increased its dividend for 16 consecutive years and has declared dividends for 349 consecutive quarters since 1937, showcasing a strong track record [7][10] Management Commitment - Pfizer's management, including CEO Albert Bourla and CFO David Denton, has reaffirmed a strong commitment to maintaining and growing the dividend over time [10][9] Patent Expiration Concerns - The company faces a significant patent cliff with key drugs like Eliquis and Xeljanz losing U.S. patent exclusivity, which could impact earnings and cash flow [10][11] - Management believes that investments in newly acquired and launched products will help offset the losses from patent expirations [11]

格隆汇12月31日｜医疗保健研究公司3 Axis Advisors数据显示，即使面对美国政府施压要求降价，但制 药商计划提高至少350种品牌药物在美国的价格，其中包括新冠病毒疫苗、呼吸道合胞病毒疫苗、带状 疱疹疫苗以及重磅癌症治疗药物Ibrance。研究指，2026年药品价格上涨的数量较去年同期增加，当时药 厂公布超过250种药品的加价计划；今年药品价格上涨的中位数约4%，与去年持平。 ...

美国制药商计划在2026年提高至少350种品牌药物的价格，尽管特朗普政府正在施压要求降价。这一提 价规模较去年同期的250多种药物有所扩大，中位涨幅约为4%，与2025年持平。 辉瑞宣布的药品提价数量最多，约80种不同药物将涨价，包括抗癌药Ibrance、偏头痛药物Nurtec和新冠 治疗药物Paxlovid，以及吗啡和氢吗啡酮等医院用药。 涉及提价的药物包括新冠、呼吸道合胞病毒和带状疱疹疫苗，以及重磅抗癌药Ibrance等。据医疗研究机 构3 Axis Advisors独家提供的数据，辉瑞、赛诺菲、勃林格殷格翰、诺华和葛兰素史克等14家与特朗普 政府就部分药品价格达成协议的药企，也计划在1月1日上调部分药物价格。 美国患者目前支付的处方药价格远高于其他发达国家，通常是后者的近三倍。特朗普一直在向药企施 压，要求将价格降至与其他富裕国家相近的水平。 这些提价不反映给药品福利管理公司的返点和其他折扣。波士顿布莱根妇女医院的卫生政策研究员 Benjamin Rome博士表示，这些协议"被宣传为变革性的，但实际上只是在边缘上做文章，并未真正解 决美国处方药高价的根本原因"。 辉瑞领涨，部分药物涨幅超四倍 辉瑞大多数 ...

智通财经APP获悉，据医疗研究公司3 Axis Advisors独家提供的数据，制药商计划提高至少350种品牌药 在美国的价格，其中包括针对COVID、呼吸道合胞病毒和带状疱疹的疫苗，以及重磅癌症治疗药物 Ibrance。此举正值特朗普政府向其施压要求降价之际。 Jardiance是美国政府为针对65岁及以上人群的医疗保险计划在2026年进行价格谈判并成功降价的10种药 物之一。根据谈判结果，Boehringer和礼来将该药价格削减了三分之二。 与去年同期相比，2026年的计划涨价药品数量有所增加，去年此时药企公布了250多种药品的提价计 划。今年的价格涨幅中位数约为4%，与2025年持平。 目前美国患者支付的处方药价格远高于其他国家，通常是其他发达国家的近三倍。特朗普一直向制药商 施压，要求其将价格降至与类似富裕国家患者支付水平相当。 这些涨幅未反映对药品福利管理商等的回扣或其他折扣。 药企亦下调部分药品价格 制药商还计划下调约9种药品的目录价格。其中包括Boehringer Ingelheim的糖尿病药物Jardiance及其三 种相关疗法降价超40%。 共同销售Jardiance的Boehringer ...

Drugmakers plan to raise U.S. prices on at least 350 branded medications including vaccines against COVID, RSV and shingles and blockbuster cancer treatment Ibrance, even as the Trump administration p... ...

Shares of Greenwich LifeSciences Inc. (GLSI) have been on a tear over the past ten days as the clinical-stage biotech pushes ahead with its financing strategy and prepares to implement risk-reducing modifications to the phase III trial of its investigational breast cancer immunotherapy, GLSI-100, upon the regulatory go-ahead.GLSI-100 is a combination of GP2 peptide vaccine and GM-CSF, an immune system booster, which is designed to help the body recognize and fight cancer cells that express the HER2/neu pro ...